SeaStar Medical (NASDAQ:ICU) Raised to “Hold” at Wall Street Zen

SeaStar Medical (NASDAQ:ICU) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Thursday.

SeaStar Medical Stock Down 1.6%

Shares of ICU opened at $1.26 on Thursday. The company has a 50-day simple moving average of $1.43 and a 200-day simple moving average of $1.80. The company has a market capitalization of $13.31 million, a PE ratio of -0.11 and a beta of -0.90. SeaStar Medical has a 52-week low of $1.11 and a 52-week high of $13.85.

SeaStar Medical (NASDAQ:ICU) last posted its earnings results on Wednesday, May 14th. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.08. The business had revenue of $0.29 million for the quarter, compared to analysts’ expectations of $0.15 million.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ICU. Geode Capital Management LLC lifted its position in SeaStar Medical by 14.1% during the fourth quarter. Geode Capital Management LLC now owns 45,430 shares of the company’s stock valued at $88,000 after buying an additional 5,618 shares in the last quarter. Tyche Wealth Partners LLC acquired a new position in shares of SeaStar Medical during the first quarter worth $63,000. Finally, Armistice Capital LLC acquired a new position in shares of SeaStar Medical during the first quarter worth $1,018,000. 1.69% of the stock is owned by institutional investors and hedge funds.

About SeaStar Medical

SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome.